Patient characteristics
| Characteristic . | No. . | % . |
|---|---|---|
| Median age, y (range) | 72 (39-86) | |
| Sex | ||
| Male | 39 | 58 |
| Female | 21 | 42 |
| Median No. of prior treatments (range) | 2 (0-7) | |
| NDMM | 12 | 20 |
| RRMM | 48 | 80 |
| Prior high-dose therapy | 33 | 55 |
| Prior anthracyclines | 22 | 37 |
| Bortezomib | 39 | 65 |
| Immunomodulatory imide drugs | 40 | 67 |
| Cardiovascular risk factors | ||
| Smoking | 26 | 43 |
| Hypertension | 22 | 36 |
| Coronary artery disease | 5 | 8 |
| Peripheral artery disease | 13 | 22 |
| Diabetes mellitus | 10 | 16 |
| Hyperlipidemia | 12 | 20 |
| Stroke | 3 | 5 |
| Arrhythmias | 4 | 6 |
| Cardiovascular disease (coronary artery disease, peripheral artery disease, stroke) | 17 | 28 |
| LVEF, % (range) | 60 (40-70) | |
| Baseline electrocardiogram | ||
| Any abnormality | 19 | 32 |
| Atrial fibrillation | 3 | 5 |
| ST-T wave abnormalities | 6 | 10 |
| Right bundle branch block | 8 | 13 |
| Left bundle branch block | 1 | 1.5 |
| Left ventricle strain | 1 | 1.5 |
| Medication | ||
| Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers | 18 | 30 |
| Calcium channel blockers | 10 | 17 |
| Beta blockers | 10 | 17 |
| Diuretics | 11 | 18 |
| Estimated glomerular filtration rate, mL/min/1.73 m2 (range) | 88 (15 to >150) | |
| Carfilzomib dose,* mg/m2 | ||
| 20/27 | 27 | 45 |
| 20/36 | 12 | 20 |
| 20/56 | 21 | 35 |
| Carfilzomib regimen | ||
| Kd | 31 | 52 |
| KRd | 17 | 28 |
| KMP | 12 | 20 |
| Characteristic . | No. . | % . |
|---|---|---|
| Median age, y (range) | 72 (39-86) | |
| Sex | ||
| Male | 39 | 58 |
| Female | 21 | 42 |
| Median No. of prior treatments (range) | 2 (0-7) | |
| NDMM | 12 | 20 |
| RRMM | 48 | 80 |
| Prior high-dose therapy | 33 | 55 |
| Prior anthracyclines | 22 | 37 |
| Bortezomib | 39 | 65 |
| Immunomodulatory imide drugs | 40 | 67 |
| Cardiovascular risk factors | ||
| Smoking | 26 | 43 |
| Hypertension | 22 | 36 |
| Coronary artery disease | 5 | 8 |
| Peripheral artery disease | 13 | 22 |
| Diabetes mellitus | 10 | 16 |
| Hyperlipidemia | 12 | 20 |
| Stroke | 3 | 5 |
| Arrhythmias | 4 | 6 |
| Cardiovascular disease (coronary artery disease, peripheral artery disease, stroke) | 17 | 28 |
| LVEF, % (range) | 60 (40-70) | |
| Baseline electrocardiogram | ||
| Any abnormality | 19 | 32 |
| Atrial fibrillation | 3 | 5 |
| ST-T wave abnormalities | 6 | 10 |
| Right bundle branch block | 8 | 13 |
| Left bundle branch block | 1 | 1.5 |
| Left ventricle strain | 1 | 1.5 |
| Medication | ||
| Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers | 18 | 30 |
| Calcium channel blockers | 10 | 17 |
| Beta blockers | 10 | 17 |
| Diuretics | 11 | 18 |
| Estimated glomerular filtration rate, mL/min/1.73 m2 (range) | 88 (15 to >150) | |
| Carfilzomib dose,* mg/m2 | ||
| 20/27 | 27 | 45 |
| 20/36 | 12 | 20 |
| 20/56 | 21 | 35 |
| Carfilzomib regimen | ||
| Kd | 31 | 52 |
| KRd | 17 | 28 |
| KMP | 12 | 20 |
Kd, carfilzomib with dexamethasone; KMP, carfilzomib with melphalan and prednisone; KRd, carfilzomib with lenalidomide and dexamethasone; NDMM, newly diagnosed multiple myeloma; RRMM, relapsed or refractory multiple myeloma.
Carfilzomib dosing: 20 mg/m2 on first 2 infusions followed by infusions at doses of 27 mg/m2 (20/27), 36 mg/m2 (20/36), or 56 mg/m2 (20/56).